DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
|
|
- Tabitha Carr
- 5 years ago
- Views:
Transcription
1 November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram
2 Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf AG financials and outlook 1 DIEBOLD NIXDORF
3 Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf AG financials and outlook 2 DIEBOLD NIXDORF
4 History of Diebold Nixdorf AG Innovation leadership Broad product portfolio Initiated banking and retail business relations Customer driven organization Integration into Siemens International expansion Optimization of internal controlling and processes Carve-out (1999) Built-up of standalone organization New brand KKR (71%), GS (18%), management and employees (11%) as shareholders Public listing of Wincor Nixdorf AG Leading provider of integrated solutions for branch and store optimization Further profitable growth Business Combination completed on August 15, DIEBOLD NIXDORF
5 Transaction and Integration Overview Nov 23, 2015 Announcement of Business Combination Agreement Feb 5, 2016 Initial Offer Acceptance Period Begins; S-4 Declared effective April 12 End of Acceptance Period Aug 15 Close Day 1 Closing Regulatory Approvals Sept. 26 Vote on Domination Agreement (DPLTA) at Wincor Nixdorf Extraordinary Shareholder Meeting Feb. 14, 2017 DPLTA effective July 05, raised DN2020 savings target from $200m to $240m New governance and organization plan Implement governance model and management structure Develop integration plans Ramp-up synergy activities Full execution 4 DIEBOLD NIXDORF
6 2016 Diebold Nixdorf Pro Forma Revenue & Adjusted EBITDA ($Millions) Revenue Non GAAP GP Non GAAP OP Adjusted EBITDA Reported Total DN $3,333 $845M $159M $266 Pro-forma Wincor Nixdorf 1 $1,652 $394M $92M $133 Pro-Forma Total DN (Non-GAAP) $4,985 $1,239M $251M $399 % of Revenue 25% 5% 8% Note 1: The company presents Wincor Nixdorf pro forma revenue for the period January 1st - August 14th 2016 as reported under IFRS and converted into USD based on our monthly rates. Diebold Nixdorf pro forma reflects the non-gaap revenue of Diebold Nixdorf combined with the pre-acquisition IFRS revenue of Wincor Nixdorf. The company presents Wincor Nixdorf pro forma Adjusted EBITDA for the periods January 1st - August 14th 2016 to facilitate future comparisons. Diebold Nixdorf pro forma reflects the Adjusted EBITDA of Diebold Nixdorf combined with the pre-acquisition Adjusted EBITDA of Wincor Nixdorf. 5 DIEBOLD NIXDORF
7 Diebold Nixdorf AG Shareholders Diebold Nixdorf AG Shareholders 1 Valuation Diebold KGaA ( a wholly-owned subsidiary of Diebold Nixdorf, Inc.) 22,921,935 or 76.9% November 23, /share Minority shares outstanding 6,894,276 or 23.1% Minority shareholder compensation 3 Cash buyout or 55.02/share Gross recurring compensation 3.13/share/year Redeemable noncontrolling interest liability 1, 4 $486 million Note 1) As of September 30, Excludes 3.3M Wincor Nixdorf treasury shares. 2) Valuation announced on November 23, 2015 which included in cash plus shares of DBD stock. 3) The adequacy of both forms of compensation payments to minority shareholders under the domination and profit-and-loss transfer agreement has been challenged by shareholders of Diebold Nixdorf AG by initiating court-led appraisal proceedings. The outcome and timing of these legal proceedings is uncertain. 4) Includes approximately $44M of pre-existing redeemable noncontrolling interests of Diebold Nixdorf AG assumed as a result of the Acquisition. 6 DIEBOLD NIXDORF
8 Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf AG financials and outlook 7 DIEBOLD NIXDORF
9 Diebold Nixdorf offers a unique combination of Services, Software and Systems Always on Value-added services ATM as a service Out-of-branch networks DN has the largest service organization focused on retail banking (~15K) Branch/store lifecycle management Lower total cost of ownership Open APIs SW orchestration layer App store Big Data analytics Cash Management Open ecosystem SOFTWARE SERVICES SYSTEMS Cash recycling Contactless transactions Encrypted touch screens Beacon technology Automation of paper processes Internet of Things POS, SCO and Kiosk Branch/store transformation 8 DIEBOLD NIXDORF
10 ATM Trends by Geographic Region Number of Bank Branches Volume of Cash Withdrawals World +0.4% World +6.4% EMEA -2.1% EMEA +2.4% Millions Americas -0.1% Millions Americas +7.2% Asia Pacific +2.3% Asia Pacific +8.4% Installed Base of ATMs by Region Millions World +3.4% EMEA +1.3% Americas +0.6% Installed Base of ATMs by Deployer Millions World +3.4% Independent ATM Deployers +2.7% Banks +3.5% Market Share of Installed Base Others 32% Asia Pacific +5.9% Note 1) Source: RBR 2017,Global ATM Market and Forecasts to DIEBOLD NIXDORF
11 Capitalizing on opportunities created by macro-trends Macro Trends Markets DN Growth Opportunities Automation / self service Digitalization BANKING Monetizing the Long Tail of Cash Individualization As a service RETAIL Connected Commerce 10 DIEBOLD NIXDORF
12 Connected Commerce Ecosystem: From Omni-Channel to Customer Centric Retail example Early consumer identification Loyalty rewards Payment options Mobile consumer engagement A B C Omni-channel will be term of the past Personalized offers Connected Commerce BANKING Personalized Bank CUSTOMER CUSTOMER CENTRIC RETAIL Store For One Fast and secure checkout in store SYSTEMS OF Engagement Operation Record Insight and intelligence Trust / Loyalty 11 DIEBOLD NIXDORF
13 Diebold Nixdorf Software Leadership Powering the largest financial institutions in the world. 11 out of the top 15 in the Americas 16 out of the top 20 in EMEA 12 of the top 20 in Asia The first end-to-end connected commerce software portfolio geared to enable secure transactions across mobile devices, ATMs, POS and SCO terminals, kiosks and online channels. 12 DIEBOLD NIXDORF
14 DN2020 Transformation Program - Achievements Sales Excellence Connected Commerce Strategy Culture / Talent Customer Finance Excellence Operational Excellence Integration Net savings of $240 million by 2020 On track to reduce ~1,000 employees by year-end 90% of supplier contracts renegotiated More than one third of planned country legal entity combinations completed. On track to consolidate 75% in Rightsizing our global manufacturing capacity in 2017 Field Service Integration finalized for ~ 80% of countries Closure of Hungary factory and Netherlands logistic center finalized OPEX reduction accelerated and ahead of plan Number of different terminals reduced by more than 50% since day 1 Production capacity reduced by 45% and now at target level Upskilling team with emphasis on services and software ~$75 million in DIEBOLD NIXDORF
15 Targeting $240M OP impact by broken down by cost type DN 2016 PF cost base OP impact E Key levers CoS Services ~ $1.8B ~$65M Services Excellence (Field Service & Replacement Parts) Further nearshoring opportunities Process excellence & global delivery infrastructure CoS Software ~ $0.3B Growth Expanding connected commerce SW offering Expand Retail SW reach to Americas Professional services excellence CoS Systems ~ $1.7B ~$70M Operational Excellence Streamline platforms, components and capacity Consolidated supplier base OPEX ~ $1.0B ~$105M Corporate & regional functional management integration Back-office / shared services integration R&D synergies and scale Total ~ $4.8B $240M Notes: 1) Gross savings significantly higher to compensate for price decrease and re-investments into growth 14 DIEBOLD NIXDORF
16 2017 Outlook Previous Guidance Current Guidance Total revenue ~$4.7B - $4.8B ~$4.6B Net Income (Loss) attributable to DN $(125)M - $(110)M $(140)M - $(130)M Adjusted EBITDA (non-gaap) $360M - $380M $370M - $380M EPS (GAAP) $(1.65) - $(1.45) $(1.80) - $(1.70) Restructuring ~$0.85 ~$0.70 Non-routine (income)/expense: Integration expense ~$0.70 ~$0.90 Legal, Acquisition, and Divestiture expense ~$0.30 ~$0.25 Impairment & Other Non-routine ~$0.05 ~$0.05 Wincor Nixdorf purchase price accounting ~$1.90 ~$2.10 Total non-routine (income)/expense ~$2.95 ~$3.30 Tax impact of restructuring and non-routine ~$(1.20) ~$(1.15) EPS (non-gaap) $ $1.15 $ $1.15 Non-GAAP effective tax rate 1 ~30% ~20% Note: The company expects a non-gaap effective tax rate of approximately 20% for the full year. With respect to the company s non-gaap tax rate outlook for 2017, the company is not providing the most directly comparable GAAP financial measure and, with respect to the company's non-gaap tax rate and adjusted EBITDA outlook for 2017, the company is not providing corresponding reconciliations because it is unable to predict with reasonable certainty those items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. These measures exclude the future impact of restructuring actions, net non-routine items, acquisition, divestiture and integration related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors and could significantly impact, either individually or in the aggregate, our future period tax rate calculated and presented in accordance with GAAP. Please see Use of Non-GAAP Financial Measures for additional information regarding our use of non-gaap financial measures. 15 DIEBOLD NIXDORF
17 Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf AG financials and outlook 16 DIEBOLD NIXDORF
18 Key Figures for Diebold Nixdorf AG Q3 2016/17 Statement of Income ( millions) 3.Q 3.Q Change 9 months 9 months Change 2016/ / / / Net sales % 1,826 1,938-6% of which Banking % 1,049 1,164-10% of which Retail % % Gross profit without restructuring expenses* % % Gross profit as a percentage of net sales 23.3% 24.6% % 24.6% - Research & development expenses without restructuring expenses* % % R&D expenses as a percentage of net sales 3.7% 3.7% - 3.7% 3.6% - Selling, general and administration expenses 5 without restructuring expenses* % % SG&A expenses as a percentage of net sales 12.5% 13.5% % 13.0% - Operating profit (EBITA) 6 without restructuring expenses* % % EBITA as a percentage of net sales (EBITA margin) 7.1% 7.5% - 7.1% 8.0% - of which Banking % % as a percentage of net sales Banking 7.1% 8.3% - 7.6% 9.3% - of which Retail % % as a percentage of net sales Retail 7.2% 6.1% - 6.3% 6.1% - Restructuring expenses* Operating profit (EBITA) 6 incl. restructuring expenses* % EBITA as a percentage of net sales (EBITA margin) 5.3% 6.8% - 5.9% 7.5% - 1) January 01, June 30, ) January 01, June 30, ) October 01, June 30, ) October 01, June 30, ) Including other operating result as well as result from equity accounted investments. 6) Profit on operating activities before interest, taxes and amortization of goodwill. 17 DIEBOLD NIXDORF
19
1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationReynolds American to Acquire Lorillard
Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationThe Dental Corporation Opportunity
The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationRAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders
Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance
More informationLeading Intimate Healthcare
21 May 2008 1 Leading Intimate Healthcare Investor presentation H1 2007/08 2 Agenda Introduction to Coloplast First 6 months 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationBank of America 38 th Annual Investment Conference. San Francisco, CA September 17 th, 2008
Bank of America 38 th Annual Investment Conference 1 San Francisco, CA September 17 th, 2008 Introduction This slide presentation contains forward-looking statements which are subject to change based on
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationInvestor Presentation. Q May 21, 2018
Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationInvestor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region
Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationJ.P. Morgan. 27 th Annual Healthcare Conference. San Francisco January 14 th, 2009
J.P. Morgan 27 th Annual Healthcare Conference 1 San Francisco January 14 th, 2009 Introduction This slide presentation contains forward-looking statements which are subject to change based on various
More informationTandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile
Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationCreating Value for Shareholders: Now and For the Long Term. October 2015
Creating Value for Shareholders: Now and For the Long Term October 2015 1 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationŚCIŚLE POUFNE. The Company's presentation
The Company's presentation Warsaw, May 2017 Key figures #1 Leader of the market of reinforced concrete prefabricated elements in Poland 4 plants manufacturing reinforced concrete prefabricated elements
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationEdwards Lifesciences. Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial
More informationOperational Efficiency:
Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationClosing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011
Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationInvestor Day Lausanne, September 29, Nicholas Rolli Vice President, Investor Relations & Financial Communications
Investor Day Lausanne, September 29, 2016 Nicholas Rolli Vice President, Investor Relations & Financial Communications PMI Investor Relations Mobile Application ("App") / Wi-Fi Access Free app available
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationTelekom Austria Group Results for the First Quarter May 16, 2007
Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More informationDainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationBuilding a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO
Building a new model of sustainable chemistry Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO Solvay at a glance Acceleration of Solvay s transformation Delivery in a challenging economic
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationSüdzucker Group Capital market forum Rhine Neckar
Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationRAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance
Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationASX Announcement 22 June 2017
ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationFully Employed MBA (MGMT FE)
Fully Employed MBA (MGMT FE) 1 Fully Employed MBA (MGMT FE) Courses MGMT FE 200. Responding to Dynamic Times: Thinking Strategically in Organizations. 6 Units. Focuses on the strategic and organizational
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationMorgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc
Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product
More informationAstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.
[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationINVESTOR DAY JUN 5, 2018 NEW YORK CITY
INVESTOR DAY JUN 5, 2018 NEW YORK CITY HOOMAN HAKAMI EVP AND GROUP PRESIDENT DIABETES GROUP FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. They are based on current assumptions
More information